Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Jubilant Pharmova Ltd - 530019 - Closure of Trading Window

 Sub: Intimation regarding Closure of Trading Window Pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company will be closed for the 'Designated Persons' from Friday, March 25, 2022 and the same shall remain closed till 48 hours after announcement of the financial results for the quarter and year ending March 31, 2022 to the Stock Exchanges. Accordingly, the Designated Persons have been intimated not to trade in the securities of the Company during the aforesaid period of closure of Trading Window.
24-03-2022

Jubilant Pharmova spikes 13% after subsidiary gets USFDA nod for depression pill

 Doxepin hydrochloride capsules, which are available in 10 mg, 25mg, 50mg, 75mg, and 100mg strengths, are the generic version of Sinequan.
21-03-2022
Bigul

Jubilant Pharmova Ltd - 530019 - Jubilant Receives ANDA Approval For Doxepin Hydrochloride Capsules

 We enclose a communication pertaining to USFDA approval. This is for your information and records.
17-03-2022
Bigul

Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be meeting Theleme Partners on March 15, 2022. The schedule may undergo change due to exigencies on the part of Investor/ Analyst/ Company. We also enclose the presentation to be used during the Virtual Meet.
14-03-2022
Bigul

Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that a share certificate has been reported to be lost by the shareholder as per the attachment. The shareholder has requested for issuance of duplicate share certificate in lieu of the original. We propose to issue Duplicate Share Certificate to the shareholder on receipt of the requisite documents. We request you to caution your members not to deal in or make any transaction in these shares. This is for your information and record.
25-02-2022
Bigul

Jubilant Pharmova Ltd - 530019 - Jubilant Pharma Limited - Credit Rating

 Dear Sirs, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Fitch Ratings has affirmed the Issuer Default Rating ('IDR') of Jubilant Pharma Limited ('JPL'), the wholly owned subsidiary of the Company, at ''BB'' and has revised the Outlook on JPL's Long-Term IDR to Negative, from Stable. Fitch Ratings has also affirmed JPL's senior unsecured rating and the rating on its USD200 million 6.00% senior unsecured notes due 2024 at ''BB''. Fitch Ratings has cited that Negative Outlook reflects its expectation of lower profitability and increase in leverage of JPL. The Company has received the Rating Action Commentary from Fitch Ratings on February 15, 2022. This is for your kind information and records.
16-02-2022
Bigul

Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that a share certificate has been reported to be lost by Mr. Kailash Laxmidas Chandan and Mr. Vijay Laxmidas Chandan claiming to be the legal heirs of the shareholder as per the attachment. Mr. Kailash Laxmidas Chandan and Mr. Vijay Laxmidas Chandan have requested for issuance of duplicate share certificate in lieu of the original. We propose to issue Duplicate Share Certificate to the legal heirs on receipt of the requisite documents. We request you to caution your members not to deal in or make any transaction in these shares. This is for your information and record.
16-02-2022
Bigul

Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In continuation of our letter dated February 4, 2022, we enclose copies of the Unaudited Consolidated Financial Results for the quarter ended December 31, 2021 published on February 5, 2022 in MINT (English) and HINDUSTAN (Hindi). We request you to take the same on record.
05-02-2022

Earnings Call for Q3FY22 Jubilant Pharmova

 Conference Call with Jubilant Pharmova Ltd. Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
05-02-2022
Bigul

Q3FY22 Quarterly Result Announced for Jubilant Pharmova Ltd.

 Pharmaceuticals company Jubilant Pharmova declares Q3FY22 result: Revenue was at Rs 1,311 Crore versus Rs 1,771 Crore in Q3'FY21 Reported EBITDA at Rs 200 Crore versus Rs 496 Crore in Q3'FY21 Finance costs at Rs 37 Crore vs. Rs 46 Crore in Q3'FY21 Effective Tax Rate of 27.7% vs. 35.6% in Q3’FY21. Current quarter benefited from reversal of certain deferred tax liabilities. PAT was at Rs 51 Crore as compared with Rs 219 Crore in Q3'FY21 EPS is Rs 3.2 versus Rs 13.75 in Q3'FY21 Capital expenditure for the quarter was Rs 112 Crore Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova Limited said: “The Company’s performance during the quarter was affected by headwinds witnessed in Pharmaceuticals segment, which was partly mitigated by continued robust performance in the Contract Research and Development Services (CRDS) segment. In the Pharmaceuticals segment, while the Radiopharma business witnessed improved performance, Generics business was affected by lower volumes due to Import Alert at Roorkee plant, latest sartan impurities issue and pricing pressure in the US generics market. Tapering of COVID related opportunities led to lower revenue and profitability in the CMO business. API business was affected due to lower volumes resulting from an unplanned plant shutdown during the quarter. Performance of API business expected to normalize in Q4’FY22. In our Contract Research and Development Services business, we continue to witness strong growth on a YoY basis driven by robust demand from our customers for our Drug Discovery Services. In the Proprietary Novel Drugs business, our lead program – LSD1/HDAC6 inhibitor has successfully received FDA clearance for IND filing and is on track for initiation of Phase 1 trials in Q4’FY22. Additional IND filings for pipeline programs to follow in FY 23. I would like to mention that over the medium term, we have strong growth levers in all our businesses. To drive growth in these businesses, Company will continue to invest accordingly.” Result PDF
04-02-2022
Next Page
Close

Let's Open Free Demat Account